Vaxcyte, Inc. (NASDAQ:PCVX) Receives $86.00 Consensus PT from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has been assigned an average rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $86.00.

A number of analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the transaction, the chief financial officer owned 104,395 shares in the company, valued at $5,979,745.60. This trade represents a 8.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares in the company, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,646 shares of company stock worth $6,570,810 in the last quarter. Insiders own 3.30% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

A number of large investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Capital Advisors Ltd. LLC acquired a new stake in shares of Vaxcyte in the 1st quarter valued at $58,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Price Performance

PCVX stock opened at $58.07 on Tuesday. Vaxcyte has a fifty-two week low of $29.29 and a fifty-two week high of $65.00. The stock has a market capitalization of $8.39 billion, a price-to-earnings ratio of -7.61 and a beta of 1.23. The business’s fifty day moving average price is $53.85 and its two-hundred day moving average price is $55.21.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the firm posted ($1.22) earnings per share. Research analysts expect that Vaxcyte will post -7.82 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.